The Inhibition of Platelet Prothrombinase Activity by Prostacyclin

R.F.A. Zwaal, P. Comfurius, H.C. Hemker, E.M. Bevers

Biomedical Centre, University of Limburg, Maastricht, The Netherlands

Abstract. Prostacyclin is able to inhibit the development of platelet prothrombinase activity. This inhibition, which also occurs with dibutyryl cAMP, is presumably due to the ability of prostacyclin to prevent the formation of a negatively charged phospholipid surface at the exterior half of the platelet membrane. Generation of this procoagulant surface, as induced by platelet activation with collagen plus thrombin, does not depend on thromboxane A₂ formation.

Introduction

In platelet rich plasma the reduction of the recalcification time and Russell's viper venom time induced by kaolin or collagen can be prevented by prostacyclin [1, 2]. These results have been taken to indicate that prostacyclin inhibits the development of platelet factor 3 activity. This activity is defined as the ability of platelets to shorten the Russell's viper venom-clotting time and therefore refers to the prothrombin converting activity of platelets.

Platelets can provide at least two components for the prothrombinase complex: factor V(V₃) and negatively charged phospholipids [3]. Factor V appears as a result of the platelet release reaction [4, 5] and small amounts of thrombin can convert it to the activated form factor V₃ [6]. This effect as such can drastically reduce the Russell's viper venom-clotting time [7, 8], and is presumably related to the ability of factor V₃ to create high affinity binding sites for factor X₃ on the platelet outer surface [9-11]. We have previously shown [12, 13] that activation of human platelets, particularly by a mixture of collagen and thrombin, is accompanied with increased exposure of negatively charged phosphatidylserine in the outer leaflet of the plasma membrane, resulting from induced transbilayer movement of phospholipids. Moreover, these platelets have been shown to enhance the conversion of prothrombin to thrombin by a complex of purified coagulation factors X₃ and V₃ in the presence of cal-
inhibition of Piatelet Prothrombinase by Prostacyclin

This catalytic activity appeared to be a function of the amount of phosphatidylerine exposed at the outer surface, when the assay is performed with excess of coagulation factors [13]. Furthermore, platelets thus activated caused a drastic reduction of the clotting time in a modified Stypven assay which has been made insensitive to release of factor V (V₄) by the platelets [7].

Since prostacyclin is known to inhibit release of all three granule constituents [14], its anticoagulant property could be explained by preventing release of factor V(V₄). We were interested to see if prostacyclin also interferes with the ability of platelets to generate a procoagulant surface of negatively charged phospholipids.

Materials and Methods

Prostacyclin was a generous gift of Dr. G. Hornstra, and was dissolved in 1 mM NaOH at the desired concentration. Aspirin (lysyl-form) and dibutyryl cAMP were from Egie and Sigma, respectively. Collagen type I was obtained from Hormon Chemie, München. In some experiments highly purified collagen type I (generous gift of Prof. J. Caen, Paris) was used, but this produced essentially the same results. Blood coagulation factors V₄, X₄ and prothrombin were purified as described in Rosing et al. [15]. Thrombin-specific chromogenic substrate H-D-phe-nylalanyl-L-pippecolyl-arginine-p-nitroanilide dihydro-chloride (52238) was from AB Kabi Diagnostica, Stockholm.

Blood was drawn from healthy male volunteers and collected in acid-citrate-dextrose (ACD; 0.052 M citric acid/0.08 M trisodium citrate/0.183 M glucose; 1 vol of ACD to 5 vol of blood). Platelet-rich plasma was obtained following centrifugation at 200 g for 15 min at room temperature. Platelets were pelleted from platelet-rich plasma at 600 g for 15 min. The platelet pellet was carefully resuspended in a buffer containing 136 mM NaCl, 2.7 mM KCl, 2.0 mM MgCl₂, 25 mM glucose, 10 mM Hepes [4-(2-hydroxyethyl)-1-piperazine ethane sulphonic acid] and 0.05% (w/v) fatty acid free human serum albumin, pH 6.6 (Hepes buffer). The platelets were washed twice in this buffer by centrifugation at 600 g for 15 min. Before each centrifugation 1 vol of ACD was added to 15 vol of platelet suspension. Finally the platelets were resuspended in Hepes buffer, pH 7.5, at a cell count of 10⁷ ml⁻¹ (Coulter counter).

Platelet activation by collagen and thrombin and measurement of platelet prothrombin converting activity was carried out essentially as described before [12, 13]. Briefly: 290 µl of the platelet suspension was activated in the presence of 15 µl 75 mM CaCl₂ by 15 µl collagen (200 µg/ml) and 5 µl thrombin (125 nM) at 37 °C. 15 min after activation, 50 µl of a freshly prepared mixture containing 30 nM factor X₄ and 60 nM factor V₄ was added. 2 min later, the enzymatic reaction was started by addition of 125 µl 16 µM prothrombin. After 1 min a sample was taken and immediately diluted in a buffer containing 120 mM NaCl, 50 mM Tris and 2 mM EDTA (pH 7.5) to stop the reaction. The amount of thrombin formed was measured by the change in absorbance at 405 nm per unit time produced by the action of thrombin on S2238, and calculated from a calibration curve made with known amounts of active-site-tritiated thrombin.

The effect of prostacyclin was measured by incubation of platelets with 5 µl prostacyclin (or 5 µl of vehicle as a control) for 30 s, prior to carrying out the activation procedure by collagen and thrombin. Incubations with dibutyryl cAMP and aspirin were done analogously for 5 min, prior to platelet activation.

Platelet release and aggregation were measured in a Chronolog lumi-aggregometer using firefly luciferin-luciferase to measure release of ATP [16]. The extent of ATP released was determined by adding the firefly luciferin-luciferase reagent 5 min after platelet activation. This was done in order to avoid influence of the ATP reagent on the aggregation behavior.

Results and Discussion

Addition of prostacyclin to platelets resulted in a dose-related inhibition of platelet prothrombinase activity as evoked by treatment with collagen plus thrombin (fig. 1, top panel). Half-maximal inhibition was observed at a prostacyclin concentration of
10 ng/ml. This is approximately 3 times higher than required to produce half-maximal inhibition of platelet aggregation and release (data not shown), and of the same order as required to inhibit platelet adhesion to collagen [20]. No inhibition was observed when prostacyclin was added after the activation procedure. The inhibitory activity of prostacyclin might be related to its ability to increase cyclic AMP concentrations in platelets [17]. Treatment of platelets with dibutyryl cAMP also produces dose-related inhibition of platelet prothrombinase activity, being half-maximal at 800 μM (fig. 1, middle panel). In order to check if the inhibitory effect of prostacyclin would depend on decreased thromboxane A₂ production of the platelets, the effect of aspirin was also measured. Aspirin up to 3 mg/ml was completely unable to inhibit platelet prothrombinase activity.
Inhibition of Platelet Prothrombinase by Prostacyclin

(fig. 1, bottom panel). This concentration is more than sufficient to produce a complete inhibition of malon-dialdehyde production by treatment of platelets with collagen and thrombin (data not shown). This suggests that thromboxane A$_2$ formation is not required to evoke platelet prothrombinase activity.

Since the assay procedure critically depends on the presence of negatively charged phospholipid while factor V$_a$ is not rate-limiting, the data suggest that prostacyclin is able to inhibit exposure of phosphatidylserine at the platelet outer surface. This would also explain why prostacyclin is able to inhibit factor X activation by factors IX$_a$ and VIII$_a$ in the presence of platelets [18]. These effects of prostacyclin may very well be responsible for the observation that in the absence of heparin, blood clotting during hemodialysis can be efficiently prevented by prostacyclin [19]. Since prostacyclin has no direct effect on coagulation factors, its potent anticoagulant action is presumably exercised via inhibition of platelet activation, not only on factor V release but also on the exposure of a procoagulant phospholipid surface. Finally, the inhibition by aspirin of so-called platelet factor-3 activity in a clotting assay as observed by others [2], is presumably caused only by inhibition of release of factor V from platelets, rather than by inhibiting exposure of procoagulant phospholipids.

References


Received: April 6, 1984
Accepted in revised form by editor J. Caen: May 16, 1984

R.F.A. Zwaal, Biomedical Centre, University of Limburg, P.O. Box 616, 6200 MD Maastricht (The Netherlands)